The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.

@article{Gibson2017TheSA,
  title={The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.},
  author={C Michael Gibson and Rim N Halaby and Serge Korjian and Yazan Daaboul and Douglas F Arbetter and Megan K. Yee and Samuel Z. Goldhaber and Russel D. Hull and Adrian F. Hernandez and Shiao-ping Lu and Olga Bandman and Janet M. Leeds and Alex Gold and Robert A. Harrington and Alexander A. Cohen},
  journal={American heart journal},
  year={2017},
  volume={185},
  pages={93-100}
}
BACKGROUND The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor. METHODS This analysis assessed the pharmacokinetics, efficacy, and safety of full- (80 mg) and reduced-dose (40 mg) betrixaban… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 30 times over the past 90 days. VIEW TWEETS
5 Citations
10 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…